Enzyme and Thermo Dual-stimuli Responsive DOX Carrier Based on PNIPAM Conjugated Mesoporous Silica.
ATRP Polymerization
Cancer
Drug Delivery
Nanoparticles
Stimuli-Responsive
Journal
Iranian journal of pharmaceutical research : IJPR
ISSN: 1726-6890
Titre abrégé: Iran J Pharm Res
Pays: Netherlands
ID NLM: 101208407
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
09
12
2021
revised:
07
02
2022
accepted:
16
03
2022
entrez:
14
3
2023
pubmed:
15
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
Stimuli-responsive drug delivery systems have been proven to be a promising strategy to enhance tumor localization, overcome multidrug resistance (MDR), and reduce the side effects of chemotherapy agents. In this study, a temperature and redox dual stimuli-responsive system using mesoporous silica nanoparticles (MSNs) for targeted delivery of doxorubicin (DOX) was developed. Mesoporous silica nanoparticles were capped with poly(N-isopropylacrylamide) (PNIPAM), a thermo-sensitive polymer, with atom transfer radical polymerization (ATRP) method, via disulfide bonds (DOX-MSN-S-S-PNIPAM) to attain a controlled system that releases DOX under glutathione-rich (GSH-rich) environments and temperatures above PNIPAM's lower critical solution temperature (LCST). Morphological and physicochemical properties of the nanoparticles were indicated using transmission electron microscopy (TEM), dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and Brunauer-Emmett-Teller (BET). The drug release tests were performed at 25°C and 41°C in the absence and presence of the DTT, and the obtained results confirmed the synergic effect of temperature and reductive agent on a dual responsive release profile with a 73% cumulative release at 41°C and reductive environment during 240 min. The average loaded drug content and encapsulation efficacy were reported as 42% and 29.5% at the drug: nanoparticle ratio of 1.5: 1. In vitro cytotoxicity assays on MCF-7 cell lines indicated significant viability decreased in cells exposed to DOX-MSN-S-S-PNIPAM compared to the free drug (DOX). Based on the results, DOX-MSN-S-S-PNIPAM has shown much more efficiency with stimuli-responsive properties in comparison to DOX on MCF-7 cancer cell lines.
Sections du résumé
Background
UNASSIGNED
Stimuli-responsive drug delivery systems have been proven to be a promising strategy to enhance tumor localization, overcome multidrug resistance (MDR), and reduce the side effects of chemotherapy agents.
Objectives
UNASSIGNED
In this study, a temperature and redox dual stimuli-responsive system using mesoporous silica nanoparticles (MSNs) for targeted delivery of doxorubicin (DOX) was developed.
Methods
UNASSIGNED
Mesoporous silica nanoparticles were capped with poly(N-isopropylacrylamide) (PNIPAM), a thermo-sensitive polymer, with atom transfer radical polymerization (ATRP) method, via disulfide bonds (DOX-MSN-S-S-PNIPAM) to attain a controlled system that releases DOX under glutathione-rich (GSH-rich) environments and temperatures above PNIPAM's lower critical solution temperature (LCST). Morphological and physicochemical properties of the nanoparticles were indicated using transmission electron microscopy (TEM), dynamic light scattering (DLS), energy-dispersive X-ray spectroscopy (EDS), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and Brunauer-Emmett-Teller (BET). The drug release tests were performed at 25°C and 41°C in the absence and presence of the DTT, and the obtained results confirmed the synergic effect of temperature and reductive agent on a dual responsive release profile with a 73% cumulative release at 41°C and reductive environment during 240 min.
Results
UNASSIGNED
The average loaded drug content and encapsulation efficacy were reported as 42% and 29.5% at the drug: nanoparticle ratio of 1.5: 1. In vitro cytotoxicity assays on MCF-7 cell lines indicated significant viability decreased in cells exposed to DOX-MSN-S-S-PNIPAM compared to the free drug (DOX).
Conclusions
UNASSIGNED
Based on the results, DOX-MSN-S-S-PNIPAM has shown much more efficiency with stimuli-responsive properties in comparison to DOX on MCF-7 cancer cell lines.
Identifiants
pubmed: 36915404
doi: 10.5812/ijpr-130474
pmc: PMC10007993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e130474Informations de copyright
Copyright © 2022, Author(s).
Déclaration de conflit d'intérêts
Conflict of Interests: The authors declare that they have no conflict of interests.
Références
Nanoscale. 2017 Oct 19;9(40):15252-15277
pubmed: 28984885
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
J Phys Chem B. 2011 Dec 22;115(50):14947-55
pubmed: 22082119
Colloids Surf B Biointerfaces. 2015 Oct 1;134:147-55
pubmed: 26188470
Front Bioeng Biotechnol. 2018 Aug 13;6:110
pubmed: 30159310
Mater Sci Eng C Mater Biol Appl. 2013 Aug 1;33(6):3426-31
pubmed: 23706230
Iran J Pharm Res. 2017 Fall;16(4):1273-1304
pubmed: 29552041
Biomed Res Int. 2014;2014:391869
pubmed: 25028650
Iran J Pharm Res. 2014 Fall;13(4):1141-8
pubmed: 25587301
Int J Pharm. 2016 Sep 10;511(1):446-454
pubmed: 27421910
BMC Cancer. 2019 Aug 1;19(1):757
pubmed: 31370818
ACS Appl Mater Interfaces. 2019 Dec 18;11(50):46497-46503
pubmed: 31738505
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Colloids Surf B Biointerfaces. 2017 Jul 1;155:41-50
pubmed: 28407530
Front Oncol. 2019 Jun 12;9:487
pubmed: 31245292
Int J Biol Macromol. 2017 Sep;102:613-624
pubmed: 28431942
Iran J Pharm Res. 2019 Winter;18(1):168-182
pubmed: 31089353
Iran J Pharm Res. 2015 Winter;14(1):27-34
pubmed: 25561909
Colloids Surf B Biointerfaces. 2017 Mar 1;151:143-155
pubmed: 27992845
J Mater Chem B. 2013;1(8):1109-1118
pubmed: 23543911
Iran J Pharm Res. 2018 Spring;17(2):460-469
pubmed: 29881404
Biomimetics (Basel). 2018 Aug 15;3(3):
pubmed: 31105244
Colloids Surf B Biointerfaces. 2020 Oct;194:111166
pubmed: 32521461
Colloids Surf B Biointerfaces. 2015 Nov 1;135:652-660
pubmed: 26335056
Colloids Surf B Biointerfaces. 2014 Jan 1;113:1-9
pubmed: 24060924
J Mater Chem B. 2013 Sep 28;1(36):4601-4611
pubmed: 32261203